Author:
Ke Jun-yu,Song Jin-bin,Li Long,He Zhen-fan,Huang Zhuo-jian,Liu Zheng-lin,Chen Gui-rong,Wang Hai-yan,Wen Su-ru,Zhou Heng-li,Ma Hui-lin,Du Qun,Wu Yong-qiang,Li Yan-wu,Chen Xin-lin
Publisher
Springer Science and Business Media LLC
Reference108 articles.
1. Low D, Mino-Kenudson M, Mizoguchi E. Recent advancement in understanding colitis-associated tumorigenesis. Inflamm Bowel Dis 2014;20:2115–2123.
2. Ephraim R, Feehan J, Fraser S, et al. Cancer immunotherapy: the checkpoint between chronic colitis and colorectal cancer. Cancers 2022;14:6131.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–535.
4. Wang Y, Ding Y, Deng Y, et al. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer. J ImmunoTher Cancer 2020;8:e000609.
5. Chen Y, Chen Y, Dong W, et al. Immunomodulation of intestinal macrophages and inlammatory bowel disease. Chin J Inflamm Bowel Dis (Chin) 2020;04:344–348.